Aurobindo
Sanjay Singh is the current Associate President of North America Operations at Aurobindo. Sanjay has over a decade of experience in the pharmaceutical industry, having previously worked as Vice President of Technical at Glenmark Pharmaceuticals from January 2007 to December 2008. In this role, they oversaw multi-location manufacturing operations and project conceptualization for Metered dose Aerosols, Nasal spray, and Tablets for European and U.S. markets in Sao Paulo, Brazil.
During their time at Glenmark Pharmaceuticals, Singh gained a deep understanding of the needs of key stakeholders and played a key role in the global team that delivers products worldwide on tight budgetary and regulatory guidelines. Sanjay also contributed to the creation of a global supply chain organization and helped establish centers of excellence within the manufacturing and allied areas.
Singh is a highly experienced and effective leader, with a proven track record in managing budgets, improving efficiency, and training and motivating employees. Sanjay has a keen eye for detail and is always looking for ways to improve processes and bottom-line results.
Sanjay Singh has a Six Sigma Green Belt certification from the Six Sigma Academy in Amsterdam. Sanjay also has an M.B.A.(PT) in finance from the Institute of Management Studies in Indore. In addition, they have a M.Pharm. in medicinal and pharmaceutical chemistry from the L.M. College Of Pharmacy. Finally, they have a B.Pharm in pharmaceutical sciences from the Devi Ahilya Vishwavidyalaya. Sanjay also has a certification from LinkedIn in operational excellence foundations.
This person is not in any offices
Aurobindo
6 followers
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.